KAMIGAKI Takashi, M.D., Ph.D.
Department of Next Generation Cell and Immunotherapy
Short Biography
| 1987 | M.D. Kobe University School of Medicine |
| 1987 | Resident, 1st Dept Surgery, Kobe University Hospital |
| 1989 | Resident, Surgery, Yodogawa Christian Hospital |
| 1995 | Ph.D. Kobe University Graduate School of Medicine |
| 1996 | Faculty Staff, Surgery, National Kobe Hospital |
| 1998 | Faculty Staff, 1st Dept Surgery, Kobe University Hospital |
| 2003 | Assistant Professor, Gastrointestinal Surgery, Kobe University Hospital |
| 2006 | Associate Professor, Gastrointestinal Surgery, Kobe University Hospital |
| 2010 | Director, Seta Clinic Osaka |
| 2010-Present | Visiting Professor, Kobe University |
| 2011-Present | Director, Clinical Research and Trial Center, Seta Clinic Group |
| 2012-2015 | Director, Seta Clin Shin-Yokohama |
| 2017-Present | Professor, Next Generation of Cell and Immunotherapy, Juntendo University Graduate School of Medicine |
Keywords
- Immunotherapy
- Dendritic Cell
- TIL, TCR-T and CAR-T
- Neoantigen
Main Research Topics and Interests
- Comprehensive Immunotherapy
- Glycolysis Control of T Cells
- Engineered T Cells and Dendritic Cells
- Genome-based Precision Immunotherapy
Publications (in English)
- Original Articles: 75
- Review Articles: 3
- h-index: 17 (Web of Science)
- Sum of Times Cited: 905 (Web of Science)
Recent Main Publications
- Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Goto S. Prognostic Factors for Advanced/Recurrent Breast Cancer Treated with Immune-cell Therapy. Anticancer Res. 2021 41(8):4133-4141.
- Hirooka Y, Kawashima H, Ohno E, Ishikawa T, Kamigaki T, Goto S, Takahara M, Goto H. Comprehensive Immunotherapy Combined with Intratumoral Injection of Zoledronate-pulsed Dendritic Cells, Intravenous Adoptive Activated T Lymphocyte and Gemcitabine in Unresectable Locally Advanced Pancreatic Carcinoma: A Phase I/II Trial. Oncotarget. 2017 9(2):2838-2847.
- Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, Okada N. Immunological Quality and Performance of Tumor Vessel-targeting CAR-T Cells Prepared by mRNA-EP for Clinical Research. Mol Ther Oncolytics. 2016 16:16024
- More